RU-22930

RU-22930

Chemical structure of RU-22930

RU-22930 is a synthetic steroid that belongs to the class of anabolic-androgenic steroids (AAS). It is a derivative of nandrolone, which is a well-known anabolic steroid used for its muscle-building properties. RU-22930 was developed in the 1970s by the French pharmaceutical company Roussel Uclaf.

Chemical Structure and Properties

RU-22930 is chemically known as 19-nor-4,9(10)-androstadienedione. It is a 19-nor derivative of testosterone, meaning it lacks a carbon atom at the 19th position, which is characteristic of nandrolone derivatives. The compound has a unique structure with a double bond between the 9th and 10th carbon atoms, which distinguishes it from other nandrolone derivatives.

The molecular formula of RU-22930 is C18H22O2, and it has a molecular weight of 270.37 g/mol. The presence of the double bond in the structure is thought to influence its binding affinity to androgen receptors and its overall anabolic activity.

Pharmacology

RU-22930 exhibits both anabolic and androgenic properties, although its anabolic effects are more pronounced. Anabolic steroids like RU-22930 promote protein synthesis and muscle growth, making them attractive for use in conditions where muscle wasting is a concern. However, the androgenic effects, which include the development of male characteristics, are also present but are typically less pronounced than the anabolic effects.

The exact mechanism of action of RU-22930 involves binding to the androgen receptor, which then influences the transcription of specific genes involved in muscle growth and development. This action is similar to other anabolic steroids, but the specific modifications in RU-22930's structure may alter its potency and side effect profile.

Clinical Use and Research

RU-22930 was primarily researched for its potential use in medical conditions that require anabolic support, such as cachexia and osteoporosis. However, like many anabolic steroids, its use in clinical practice has been limited due to concerns about side effects and the potential for abuse.

Research into RU-22930 has also focused on its potential to provide anabolic benefits with reduced androgenic side effects, which is a common goal in the development of new anabolic steroids. However, detailed clinical studies and trials are limited, and much of the information available is based on preclinical research.

Side Effects

As with other anabolic steroids, the use of RU-22930 can lead to a range of side effects. These may include liver toxicity, cardiovascular issues, and endocrine disruption. The androgenic effects can also lead to virilization in women and gynecomastia in men. Long-term use of anabolic steroids is associated with significant health risks, and their use is generally discouraged outside of specific medical indications.

Legal Status

RU-22930, like many anabolic steroids, is classified as a controlled substance in many countries. Its use is restricted to specific medical conditions, and it is not approved for use in athletic performance enhancement. The potential for abuse and the associated health risks have led to strict regulations regarding its distribution and use.

Related Pages

• Anabolic steroid
• Nandrolone
• Androgen receptor
• Steroid hormone